IDEAS home Printed from https://ideas.repec.org/a/adp/jctoij/v8y2017i3p51-54.html
   My bibliography  Save this article

Emergence of Novel Agents for Treatment of Hodgkin Lymphoma

Author

Listed:
  • Nahla AM Hamed

    (Department of Hematology, Alexandria University, Egypt)

Abstract

cHL patients are generally classified in 1 of 3 groups: early-stage favorable, early-stage unfavorable or advanced-stage disease. Prognostication in advanced-stage patients is defined by the IPS. Patients with low-risk IPS are treated with 6 cycles of standard ABVD, whereas high-risk patients are initially treated with the more intensive German-derived regimen, escalated BEACOPP. Treatment may be further refined through PET-adapted therapy. The optimal chemotherapy for advanced stage HL can be endlessly debated. Based on recent study results, two classes of drugs stand out as highly active in advanced HL: antibody-drug conjugates (BV) and programmed death 1 inhibitors (Nivolumab). There are abundant salvage therapy options for patients with R/R HL. The choice of salvage chemotherapy therapy is becoming increasingly difficult in the era of novel agents.

Suggested Citation

  • Nahla AM Hamed, 2017. "Emergence of Novel Agents for Treatment of Hodgkin Lymphoma," Cancer Therapy & Oncology International Journal, Juniper Publishers Inc., vol. 8(3), pages 51-54, December.
    • Handle: RePEc:adp:jctoij:v:8:y:2017:i:3:p:51-54
    DOI: 10.19080/CTOIJ.2017.08.555737
    as

    Download full text from publisher

    File URL: https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555737.pdf
    Download Restriction: no
    File URL: https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555737.php
    Download Restriction: no
    File URL: https://libkey.io/10.19080/CTOIJ.2017.08.555737?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:adp:jctoij:v:8:y:2017:i:3:p:51-54. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Robert Thomas (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.